WEBINARS
Our webinars allow users to learn from experts and earn continuing education credits on industry topics, progress in research, services available, and more.
Show More
-
OCT 18, 2018 | 7:00 AM
DATE: October 18, 2018TIME: 7:00AM PDTExperimental Design Best Practice for Multicolor Flow CytometryMulticolor flow cytometry is a critical technique for many scientific... -
OCT 17, 2018 | 9:00 AM
DATE: October 17, 2018TIME: 09:00am PT, 11:00pm CT, 12:00pm, ET Each patient case request can vary in what is required to make a diagnosis by the pathologist.Many times, the patholog...
-
OCT 16, 2018 | 7:00 AM
DATE: October 16, 2018TIME: 7:00am PDT, 10:00am EDT In today’s healthcare environment, leaders are increasingly asked to demonstrate value in terms...
-
OCT 16, 2018 | 7:00 AM
DATE: October 16, 2018TIME: 7:00m PDT, 10:00am EDT 22q11 Deletion Syndrome (22q11DS) is a genomic disorder caused by a microdeletion of chromosome 22 that occurs...
-
OCT 16, 2018 | 6:00 AM
DATE: October 16, 2018TIME: 3:00 PM CEST, 6:00 AM PDT This webinar will provide an overview on some pathogens that can be transmitted from mother to fetus du...
-
OCT 12, 2018 | 8:00 AM
The D-dimer can be a useful tool in the management of patients with suspected or established venous thromboembolism (VTE). One use is in the assessment of a patient who presents with symptoms...
-
OCT 11, 2018 | 1:30 PM
As the most common female malignancy, breast cancer is the most likely reason that a woman will die of cancer around the world. Breast cancer mortality has dropped in the U.S. by 35% since 19...
OCT 11, 2018 | 1:30 PM
Recent work has identified epigenomic features of distal regulatory elements to be dynamic and defining indicators of cellular specification and transformation. Of particular relevance is our...
OCT 11, 2018 | 12:00 PM
Lung cancer is the leading cause of cancer-related mortality worldwide. Large-scale sequencing studies have revealed the complex genomic landscape of NSCLC and genomic differences between lun...
OCT 11, 2018 | 12:00 PM
Although targeted therapies often elicit profound initial patient responses, these effects are transient due to residual disease leading to acquired resistance. How tumors transition between...
